Certain types of skin cancers and blindness due to age-related macular degeneration (AMD) and diabetic retinopathy are likely to be among the first uses for the drug. AMD is the most common cause of blindness in Australia (Macular Degeneration Foundation).
The experimental drug has already been shown to be effective on skin cancers in pre-clinical models, in another paper published this month by Professor Khachigian's team in the journal, Oncogene.
"This may be a 'one-size fits all' therapy, because it targets a master regulator gene called c-Jun which appears to be involved in all of these diseases," said UNSW Professor Levon Khachigian, of the Centre for Vascular Research (CVR), who is the senior author of the Nature Biotechnology paper.
"c-Jun is an important disease-causing gene," said Professor Khachigian, a molecular biologist. "It stands out because we don't see much of it in normal tissue but it is highly expressed in diseased blood vessels, eyes, lungs, joints, and in the gut – in any number of areas involving inflammation and aggressive vascular growth.
"Our experimental drug, Dz13, is like a secret agent that finds its target, c-Jun, within the cell and destroys it," he said. "It is a specific, pre-programmed 'molecular assassin'."
The paper in Nature Biotechnology shows the potential of c-Jun as a drug target in inflammation. It details tests in a variety of pre-clinical models showing how effective Dz13 is in problems such as eye disease and arthritis.
The next phase in the therapy's development would be a trial, involving up to 10 people with non-melanoma skin cancers. The tumours would be injected with the drug over an eight-week period.
"If such a trial were successful, it would be a significant development given the high rates of skin cancer and because the main treatment currently is surgical excision, which can cause scarring," said Professor Khachigian.
"Conventional anti-inflammatory drugs are associated with a whole host of side-effects. Our therapeutic may potentially avert some of these."
A third paper using the same technology, but focusing on a different master regulator, Egr-1, has also been published this month by Professor Khachigian's group in the Journal of Thrombosis and Haemostasis and shows that heart muscle damage is reduced by the drug after a heart attack.
Susi Hamilton | EurekAlert!
Climate Impact Research in Hannover: Small Plants against Large Waves
17.08.2018 | Leibniz Universität Hannover
First transcription atlas of all wheat genes expands prospects for research and cultivation
17.08.2018 | Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung
New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference
Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
17.08.2018 | Event News
08.08.2018 | Event News
27.07.2018 | Event News
17.08.2018 | Physics and Astronomy
17.08.2018 | Information Technology
17.08.2018 | Life Sciences